Track market-moving stories before they get noisy

CN (CNI) reported earnings 30 days ago. What's next for the stock?

MONTREAL, June 03, 2026 (GLOBE NEWSWIRE) -- Janet Drysdale, Executive Vice-President and Chief Commercial Officer and Patrick Whitehead, Executive Vice-President and Chief Operating Officer of CN (TSX: CNR) (NYSE: CNI), will address the Wells Fargo 16th Annual Industrials and Materials Conference on June 11, 2026, at 9:45 a.m. Eastern Time (ET).

MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that propane export shipments from South Beamer, Alberta to Watson Island, British Columbia reached an all-time monthly record for the corridor in May, while staying within the existing commercial arrangements. The achievement represents an increase in carloads of 40% compared to May 2025 and beating CN's previous monthly record from August 2024, reflecting continued operational improvements across the supply chain.

BHP inks rail deals with CNI and CP, giving the Jansen potash project dual access to Vancouver's Westshore as first production nears.

Key Takeaways CNI secured a transport agreement with BHP for the Jansen Potash Mine in Saskatchewan. Canadian National Railway will move potash to Canada's West Coast export terminals. CNI could benefit from higher shipment volumes and a stronger bulk commodity business. Canadian National Railway (CNI - Free Report) strengthened its long-term growth prospects by securing a transportation agreement with BHP for the Jansen Potash Mine, one of the world's largest new potash developments. The agreement positions CNI to transport potash from Saskatchewan to export terminals on Canada's West Coast, creating a new avenue for freight growth and reinforcing its role in supporting Canada's resource economy.

The deal highlights the strategic advantage of CNI's extensive rail network, which efficiently connects resource-producing regions with key export gateways. As production at the Jansen mine ramps up, CNI stands to benefit from higher shipment volumes, improved network utilization and increased participation in the growing potash export market. The agreement also strengthens the company's bulk commodity franchise, a key contributor to its overall revenue base.

Potash remains a critical component of global fertilizer production, and rising demand for agricultural products should support long-term growth in fertilizer exports. By partnering with BHP on this landmark project, CNI positions itself to capitalize on durable agricultural and commodity demand trends while deepening its relationship with a major global mining company.

Overall, the agreement reflects CNI's ability to secure strategic, long-duration transportation contracts that support future volume growth. As the Jansen project advances toward full production, CNI could benefit from sustained freight demand, enhancing revenue visibility and strengthening its position as a leading North American rail transportation provider.

CNI’s Share Price PerformanceCNI’s shares have gained 23.2% in the past six months compared with the Transportation - Rail industry’s 20% growth.

Image Source: Zacks Investment Research

CNI’s Zacks RankCNI currently carries a Zacks Rank #3 (Hold).

Stocks to ConsiderInvestors interested in the Zacks Transportation sector may consider Expeditors International of Washington, Inc. (EXPD - Free Report) and International Seaways (INSW - Free Report) . 

EXPD currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Expeditors has an expected earnings growth rate of 11.9% for the current year.  The company has an encouraging earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 13.96%.

INSW currently sports a Zacks Rank #1.

INSW has an expected earnings growth rate of more than 100% for the current year. The company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 33.93%.

Here we pick two railroad stocks, UNP and CNI, which have a solid five-year dividend growth history.

On April 27, 2026, Crown Castle Inc (CCI) shares fell 3.4% to $83.44. Over the past year, the stock has experienced significant volatility, trading between a 52

Most REITs are not ideal “forever” holdings. A few REITs have rare long-term compounding potential. Three unique landlords could keep growing for decades.

On June 04, 2026, Crown Castle Inc CCI shares rose 5.8% to a current price of $93.79. The stock has shown a 52-week range of $75.96 to $115.76, indicating significant volatility over the past year. The recent price increase reflects a positive sentiment in the market, despite the stock's overall performance being slightly negative year-over-year.

GF Value™ verdict: CCI is currently priced at $93.79, which is 4.3% above its GF Value™ estimate of $89.90.GF Score™: 62/100, indicating an above-average ranking based on key performance metrics.Most notable signal: Insiders have bought $0.1M worth of shares in the last three months, signaling confidence in the company's future. Is CCI Overvalued or Undervalued? According to the GF Value™, Crown Castle Inc is currently overvalued. The stock's price of $93.79 exceeds the GF Value™ estimate of $89.90 by 4.3%. This indicates a lack of margin of safety for prospective investors, as the stock is trading above its intrinsic value. The GF Valuation label classifies the stock as “Fairly Valued,” suggesting that while it is not severely overvalued, there are risks associated with its current price level. Investors should consider the potential for price corrections or stagnation in growth as the market adjusts to the valuation metrics.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given the current price in relation to the GF Value™, it is important for investors to weigh the risks of entering a position at this valuation against the potential for future growth.

How Does CCI's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 38.8x 37.8x Forward P/E 42.2x N/A The current P/E ratio of 38.8x is 3% above its 5-year median P/E of 37.8x. Additionally, the forward P/E of 42.2x indicates that analysts expect earnings growth; however, this level also suggests that the stock is trading at a premium compared to its historical valuation metrics. This P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that CCI is presently overvalued.

What Does CCI's GF Score™ Tell Us? Metric Rating GF Score™ 62 Financial Strength 2/10 Profitability 7/10 Growth 1/10 Valuation 9/10 Momentum 5/10 The GF Score™ of 62/100 indicates that Crown Castle Inc is positioned above average in terms of potential long-term returns. However, the company exhibits weaknesses in Financial Strength and Growth, with ratings of 2/10 and 1/10 respectively. On the other hand, it shows strong profitability with a rating of 7/10 and a robust Valuation score of 9/10. This mixed performance suggests that while CCI has favorable valuation metrics, its financial stability and growth prospects may raise concerns for long-term investors.

What Are Insiders Doing with CCI Stock? In recent months, insider activity has shown a positive trend as insiders have purchased $0.1 million worth of Crown Castle Inc shares without any selling activity reported. This pattern of buying can often be interpreted as a signal of confidence from those with intimate knowledge of the company’s operations and prospects. Such insider purchases may indicate that they believe the stock is undervalued at current levels and expect future price appreciation.

What This Means for Investors Based on the GF Value™ assessment, Crown Castle Inc is currently overvalued. With its price exceeding the intrinsic value estimate by 4.3%, potential investors should approach with caution, considering both the market's sentiment and the company's financial standing.

For the complete analysis, visit the Crown Castle Inc CCI stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is CCI's GF Score™?

CCI's GF Score™ is 62/100, indicating an above-average ranking based on financial strength, profitability, growth, valuation, and momentum, which suggests it may generate higher long-term returns.

Is CCI overvalued or undervalued?

CCI is currently overvalued according to the GF Value™, with its price of $93.79 exceeding the GF Value™ estimate of $89.90 by 4.3%.

What is CCI's P/E ratio?

CCI's P/E (TTM) ratio is 38.8x, which is 3% above its 5-year median P/E of 37.8x, suggesting that the stock is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Toronto, Ontario--(Newsfile Corp. - June 10, 2026) - Canadian Copper Inc. (CSE: CCI) ("Canadian Copper" or the "Company") today announced that a court hearing in Vancouver, Canada is scheduled on June 29th, 2026, at 10AM (PST) to approve the Caribou Complex transaction. Next Steps After Court Hearing The Company, as buyer, and FTI Consulting Canada Inc. the court appointed Receiver of Trevali Mining New Brunswick Ltd.

Coupang, Inc. (CPNG - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this company have returned -20% over the past month versus the Zacks S&P 500 composite's +8.8% change. The Zacks Internet - Commerce industry, to which Coupang belongs, has gained 9.7% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Coupang is expected to post a loss of $0.14 per share for the current quarter, representing a year-over-year change of -800%. Over the last 30 days, the Zacks Consensus Estimate has changed -400%.

For the current fiscal year, the consensus earnings estimate of -$0.17 points to a change of -241.7% from the prior year. Over the last 30 days, this estimate has changed -15.9%.

For the next fiscal year, the consensus earnings estimate of $0.4 indicates a change of +336.8% from what Coupang is expected to report a year ago. Over the past month, the estimate has changed -33.3%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Coupang is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Coupang, the consensus sales estimate for the current quarter of $8.93 billion indicates a year-over-year change of +4.8%. For the current and next fiscal years, $37.75 billion and $42.7 billion estimates indicate +9.3% and +13.1% changes, respectively.

Last Reported Results and Surprise HistoryCoupang reported revenues of $8.5 billion in the last reported quarter, representing a year-over-year change of +7.5%. EPS of -$0.15 for the same period compares with $0.06 a year ago.

Compared to the Zacks Consensus Estimate of $8.57 billion, the reported revenues represent a surprise of -0.72%. The EPS surprise was +74.58%.

Over the last four quarters, Coupang surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Coupang is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Coupang. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Coupang, Inc. (CPNG - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this company have returned -21.4% over the past month versus the Zacks S&P 500 composite's +4.8% change. The Zacks Internet - Commerce industry, to which Coupang belongs, has gained 1.2% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Coupang is expected to post a loss of $0.14 per share, indicating a change of -800% from the year-ago quarter. The Zacks Consensus Estimate has changed -640% over the last 30 days.

The consensus earnings estimate of -$0.17 for the current fiscal year indicates a year-over-year change of -241.7%. This estimate has changed -13.3% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $0.4 indicates a change of +336.8% from what Coupang is expected to report a year ago. Over the past month, the estimate has changed -31%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Coupang.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Coupang, the consensus sales estimate for the current quarter of $8.93 billion indicates a year-over-year change of +4.8%. For the current and next fiscal years, $37.75 billion and $42.7 billion estimates indicate +9.3% and +13.1% changes, respectively.

Last Reported Results and Surprise HistoryCoupang reported revenues of $8.5 billion in the last reported quarter, representing a year-over-year change of +7.5%. EPS of -$0.15 for the same period compares with $0.06 a year ago.

Compared to the Zacks Consensus Estimate of $8.57 billion, the reported revenues represent a surprise of -0.72%. The EPS surprise was +74.58%.

Over the last four quarters, Coupang surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Coupang is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Coupang. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

It can be frustrating to watch a stock you own flounder while the rest of the market seems to climb to new heights every day. But if the business is continually growing in value, patience will eventually be rewarded for those who hold it over the long term.

This describes Coupang (CPNG 2.29%) perfectly. The stock is down 67% from its initial public offering (IPO) a little over five years ago and has suffered further pain in recent months due to a data leak scandal. At the same time, revenue is up close to 200% cumulatively since its IPO.

A combination like this makes Coupang a once-in-a-decade buying opportunity. Here's why investors should consider adding the stock to their portfolios today.

Today's Change

(

-2.29

%) $

-0.40

Current Price

$

16.86

The other side of a data leak scandal Coupang sold stock in its 2021 IPO at $35 a share and then saw it jump to $63.50 on its first day of trading. It then fell to just above $10 in the 2022 bear market. All the while, revenue for its e-commerce and online subscription ecosystem kept compounding to new heights.

The stock had been recovering over the last few years and peaked above $30 in late 2025. But then a new headwind emerged: a data leak scandal in late 2025. Coupang's customer data was leaked by a rogue former employee, leading to outrage in South Korea that spilled over into the government's trade negotiations with the United States.

A small boycott of Coupang's platform led to a slight deceleration in active customers from Q4 2025 to Q1 2026. On the Q1 conference call, management said it had already recovered 80% of these lost customers by the end of April, meaning this was barely a two-quarter speed bump. Total revenue grew 8% year over year last quarter to $8.5 billion, with an expectation for acceleration later this year once the data leak scandal is fully over.

Coupang stock remains down around 50% from its 2025 high, sitting at about $16.50 today.

Image source: Getty Images.

Replicating the business worldwide South Korea should remain a solid growth driver for Coupang. It doesn't hurt that the country's economy is booming because of its specialty in memory chips for the artificial intelligence (AI) revolution. Expect durable double-digit growth from continued e-commerce expansion in the region.

More explosive growth may come from its new expansion into Taiwan. The country has a population of 23 million, is wealthy, and also serves as a hub for AI chip production. Coupang's new business in Taiwan is at a "hypergrowth rate," according to management on the conference call, but it is currently losing a lot of money. Over the next few years, this segment should continue to scale and eventually generate billions, if not over $10 billion, in revenue for Coupang.

CPNG EBIT Margin (TTM) data by YCharts

Why Coupang stock is incredibly cheap The steady growth of Coupang's South Korean e-commerce marketplace and the rapid expansion in Taiwan should assure double-digit revenue growth in the years ahead, not to mention its ancillary businesses, such as food delivery, rapid delivery, financial technology services, and a new intelligent cloud business. These rising tides can grow Coupang's revenue from $35 billion over the last 12 months to $70 billion in five years.

A larger question is what profit margins will be five years from now. Coupang operates today at close to breakeven, making it difficult to value on a price-to-earnings ratio (P/E) basis. What we do know is that the core South Korean e-commerce segment had an EBITDA (earnings before interest, taxes, depreciation, and amortization) of 5%, with Q4 coming in at 7.7% before the data leak scandal.

This indicates the potential for significant consolidated operating leverage in the years ahead as new projects, such as Taiwan, begin to mature. If Coupang can grow its revenue to $70 billion with a 10% profit margin, that is $7 billion in annual earnings power.

Coupang's market value today is just under $30 billion. For investors with the patience to hold for five years, Coupang looks like a bargain stock trading at under 5x forward earnings based on these growth assumptions.

Sitting here today, with stocks like Micron Technology zooming past a $1 trillion market cap and delivering 10x gains in a year, can make you feel like there is no opportunity left to buy artificial intelligence (AI) stocks. Stocks like Nvidia have been soaring for the last few years, and now trade at premium valuations with major downside risks if the AI spending boom peters out.

What if I told you there were still cheap AI stocks to buy? You just have to look abroad in order to find them. Here's why Coupang (CPNG 2.29%) is the one AI stock you can buy right now if you missed out on Nvidia, Micron, and other winners of the last few years.

Today's Change

(

-2.29

%) $

-0.40

Current Price

$

16.86

AI tech company in South Korea Coupang's main business is an e-commerce marketplace, built in a similar manner to Amazon. Unlike the mainline AI companies in Silicon Valley, Coupang is using AI from a robotics and automation perspective across its vast network of warehouses in South Korea. It wants to maximize the use of robots in its warehouses to save time and money and deliver items to customers faster.

Outside of e-commerce, Coupang utilizes AI within its advertising, financial technology, and food delivery divisions. It wants to use automation to improve the customer journey while simultaneously maximizing profits. AI is more than the chatbots popular with consumers today.

In a more direct investment, Coupang recently launched what it calls the Coupang Intelligent Cloud (CIC), which is building AI data centers for itself and, potentially, third-party customers. Sitting less than a year after the announcement, it is unclear exactly how ambitious Coupang plans to invest in its AI cloud, but it shows how laser-focused the technology company is on layering in AI into its business.

Image source: Getty Images.

Huge economic growth opportunity There are 24 million active Coupang customers, which is close to half the population of South Korea. They flock to the service because of its rapid delivery and wide product selection at low prices. Over the last 12 months, the business has generated $35 billion in revenue, primarily from its e-commerce platform in South Korea.

We may see a catalyst in consumer retail spending in South Korea, and it is entirely related to the AI boom. Supply shortages for memory chips are driving up prices, which greatly benefits South Korean semiconductor giants Samsung and SK Hynix. Because of this massive profit boost, the two companies are paying bonuses to employees that could total $40 billion combined in 2026. With total national income at $1 trillion, this is a 4% increase that goes straight to customer wallets to spend on discretionary items, hopefully on Coupang.

Over the long term, greater spending on e-commerce than on in-person shopping should drive growth for Coupang and its expansion into other categories, such as food delivery. It has also made an aggressive expansion play into Taiwan, where revenue is growing by more than 100% year over year -- albeit from a small base -- according to management.

CPNG Revenue (TTM) data by YCharts

Why Coupang stock is a fantastic buy today A lot of moving parts could impact Coupang's profitability in the near term. It may get a boost from this South Korean memory chip boom, while headwinds to profits may arise from rising losses from its expansion into Taiwan.

What matters is the customer loyalty being built through Coupang's superior service offering, leading to durable revenue growth and long-term operating leverage. Right now, Coupang has a market cap of only $29.55 billion and revenue of $35 billion. Revenue should grow durably, driven by multiple tailwinds. Assuming a 12% revenue growth rate, Coupang's revenue will have close to doubled to $61.7 billion five years from now.

A measly 10% profit margin on this $61.7 billion in revenue is $6.2 billion in earnings, or less than 5 times its current market value. This makes Coupang stock incredibly cheap. Stay patient, Coupang can be the tech stock that delivers massive gains in your portfolio over the next five years, just as Nvidia has for the last five.

Coupang, Inc., a U.S.-based technology leader, today was named to the Fortune 500® for the fourth consecutive year, jumping 10 places to No. 132 as it continues to grow and advance its innovative global fulfillment and logistics network. The Fortune 500® ranks the largest U.S. companies by total revenue each year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603035002/en/

Coupang climbs 10 spots on the Fortune 500 to No. 132

Seattle-based Coupang generated $34.5 billion in revenue in 2025, an increase of 14% over the prior year, powered by its focus on innovation, customer service and expansion in new markets.

Coupang has set a new standard for speed and quality in online services, applying artificial intelligence across its operations to help businesses, including in the U.S., reach new international customers. Coupang has operations and support services in geographies including the U.S., Korea, Taiwan, Singapore, China, India, Japan and across Europe. Its reach spans more than 190 countries and territories, connecting tens of millions of customers to quality products.

Enabling cross-border commerce at scale

“As a U.S. technology company, Coupang is redefining global commerce and driving economic expansion by bridging the gap between businesses and customers worldwide,” said Robert Porter, Coupang chief global affairs officer. “Last year, our strategic investments in advanced AI, custom robotics and cutting-edge logistics drove over $5 billion in exports of U.S. goods and services. Building on this momentum, we will continue to seek to create unprecedented opportunities for businesses across the United States, Korea, Taiwan and Japan, and for customers in all 190 markets we serve.”

Coupang provides end-to-end logistics solutions that help businesses grow in new markets. The company works with businesses from cherry farmers in the U.S. to olive oil artisans in Italy and skilled textile crafters in Japan to sell to new customers outside their home countries. Coupang supports their growth through a range of turn-key services to help them compete and thrive, including fulfillment and logistics solutions, marketing, customer service and export assistance to connect their products to global customers.

In 2025, Coupang enabled the sale of billions of dollars' worth of goods and services from U.S. businesses to international markets. In South Korea, small business sellers on Coupang grew their sales by 21% in 2025, more than 100 times the national small business growth rate.

Coupang also connects global luxury brands with customers worldwide through Farfetch. With more than 1,400 brands, boutiques and department stores, Farfetch serves customers in 190 countries and territories with the United States as its largest market, accounting for millions of customers.

Driving rapid growth in Taiwan

Coupang is accelerating its growth and investment in Taiwan. The company opened its fourth smart fulfillment and logistics center in Taiwan in 2026, expanding the company’s advanced global logistics network in the country. This technology powers Rocket Delivery, which now reaches across approximately 70% of Taiwan’s geography, providing next-day delivery seven days a week. Coupang has invested in Taiwan across multiple phases, including the largest approved U.S. investment in Taiwan last year and the second-largest approved foreign investment overall.

Technology driving global commerce

Coupang has invested billions of dollars in artificial intelligence, robotics and cloud computing to support the growth of its global operations. Its logistics network uses AI to forecast demand, streamline fulfillment and optimize delivery across regions. These systems are powered by Coupang Intelligent Cloud, enabling scalable AI training and real-time data processing. Since its founding in 2010, Coupang has developed an integrated technology and logistics ecosystem designed to deliver fast, reliable service across diverse markets.

Recognized for innovation and impact

Coupang’s innovation continues to receive international recognition. In 2026, it was named to the LexisNexis Top 100 Global Innovators list for the second consecutive year. The company also ranked No. 2 in Fast Company’s 2025 list of the World’s Most Innovative Companies in the Retail category.

About Coupang

Coupang is a technology and Fortune 150 company listed on the New York Stock Exchange (NYSE: CPNG). It provides retail, restaurant delivery, video streaming, and fintech services globally through brands including Coupang, Eats, Play, Rocket Now, and Farfetch.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260603035002/en/

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Coupang, Inc. (CPNG - Free Report) .

Coupang currently has an average brokerage recommendation (ABR) of 1.97, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 15 brokerage firms. An ABR of 1.97 approximates between Strong Buy and Buy.

Of the 15 recommendations that derive the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 53.3% and 6.7% of all recommendations.

Brokerage Recommendation Trends for CPNG

Check price target & stock forecast for Coupang here>>>

While the ABR calls for buying Coupang, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in CPNG?In terms of earnings estimate revisions for Coupang, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at -$0.17.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Coupang. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Coupang.

SummaryCompaniesRegulator says Coupang's lack of safety measures led to data breachPenalty amounts to 1.4% of Coupang's revenue in 2025Coupang apologises for concern it caused customers and the publicSEOUL, June 11 (Reuters) - South ​Korea will fine e-commerce giant Coupang (CPNG.N), opens new tab 625 billion won ($409.30 million) over a massive leak of ‌customer information last year and illegal collection of personal information, in the country's largest data breach penalty on a company.

The Personal Information Protection Commission said the New York-listed company had leaked personal data of more than 33 million customers and failed to detect the breach within ​the 72 hours required by the law.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The fine amounts to 1.4% of Coupang's revenue of 45 trillion ​won in 2025, according to Reuters' calculation.

"This accident occurred due to Coupang's lack of safety ⁠measures and systems, not sophisticated hacking," Song Kyung-hee, the chairperson of the privacy regulator, told a briefing on Thursday.

After ​the fine was announced, Coupang apologised for having caused concern to the public and its customers.

However, the company said ​that "we regret that our proactive measures to prevent secondary harm from last year's data leak incident, as well as our explanations based on clear facts, were not sufficiently reflected" in the regulator's decision.

Seattle-based Coupang generates most of its revenue in South Korea, offering fast ​delivery of groceries, food and other goods.

The penalty followed a finding by a government-led investigation earlier this year that blamed ​the breach on management failure.

Coupang logo is seen in this illustration taken February 11, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

South Korea's science ministry at the time said that a former employee, who was a Chinese national, ‌stole a ⁠security key and gained unauthorised access to customer accounts.

Song said Coupang's security system allowed a hacker to easily access the personal information of all of its customers, even after the suspect left the company.

The firm also failed to detect an unusual increase in traffic to its customer data until it was alerted by a customer's inquiry, she added.

Separately, ​the regulator found the company's ​marketing program illegally collected ⁠information on online activities of around 11 million customers without their agreement, Song said.

Probes into the data breach added to trade friction with Washington amid concerns Korean authorities had gone ​too far in their treatment of the U.S.-listed company, while the allies have ​been negotiating details ⁠on a trade deal struck last year.

South Korea said, however, its Coupang probe was neither a trade nor security issue and should be handled separately from the ongoing talks with Washington.

The firm is estimated to control about 40% of South Korea's logistics ⁠services, the ​largest market share among peers, according to Seoul-based IM Securities.

"Coupang has grown ​its e-commerce service significantly based on vast customer data," Song said. "But the company did not have a system to protect and manage customer ​information despite its business scale."

($1 = 1,527.0000 won)

Reporting by Heejin Kim and Joyce Lee; Editing by Himani Sarkar and Sonali Paul

Our Standards: The Thomson Reuters Trust Principles., opens new tab

South Korean authorities have imposed a record-breaking fine of $624 billion won (over $400 million) on retail giant Coupang after a data breach last year compromised the personal data of more than 34 million customers.

Seoul’s Personal Information Protection Commission issued the maximum penalty on Thursday following discovery of the breach in December 2025. The retail giant, which is headquartered in the U.S. but popular in South Korea and likened to the “Amazon of Asia,” had said the months-long data breach allowed a former employee to obtain names, email and shipping addresses, phone numbers, and order histories of about two-thirds of South Korea’s population.

Coupang told BBC News that it plans to challenge the regulator’s decision. The fine represents a rare case of a financial penalty issued against a U.S.-based firm. Korean lawmakers have accused some of their American counterparts of imposing political pressure after reports that U.S. representatives were linking the data breach with U.S.-South Korean bilateral ties in response to the case against Coupang’s executives.

U.S. companies rarely face financial sanctions or criminal prosecution for data breaches as a result of lacking laws and enforcement powers.

Today's Change

(

-2.29

%) $

-0.40

Current Price

$

16.86

Coupang (CPNG 2.29%), a South Korean e-commerce platform offering diverse products and services, closed Thursday at $17.27, up 14.25%. The stock moved higher after regulators finalized a record privacy fine that came in below worst-case fears. Investors are watching how the charge affects 2026 earnings. Trading volume reached 67.8 million shares, about 197% above its three-month average of 22.8 million shares. Coupang IPO'd in 2021 and has fallen 65% since going public.

How the markets moved todayThe S&P 500 added 1.73% to finish Thursday at 7,393, while the Nasdaq Composite climbed 2.54% to close at 25,810. Within internet retail, industry peers Alibaba Group closed at $112.69, down 2.33%, and JD.com finished at $28.06, off 1.37%, lagging Coupang’s rally.

What this means for investorsIn the latest example of just how much the market hates uncertainty, shares of Coupang are up 14% today after the South Korean e-commerce company received a smaller-than-expected $409 million fine from the Personal Information Protection Commission (PIPC). Coupang was hit by a data breach in November of 2025, and the PIPC argued that the company “did not have a system to protect and manage customer ​information despite its business scale."

Now with certainty around the size of the penalty, I think we can turn our attention back to Coupang’s promising operations. Coupang issued a $1.2 billion voucher to affected shoppers last year and announced it had recovered roughly 80% of the members it had lost from the breach, so I see it as an interesting opportunity, down over 40% in the last year.

Josh Kohn-Lindquist has positions in Coupang. The Motley Fool recommends Alibaba Group, Coupang, and JD.com. The Motley Fool has a disclosure policy.

-

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 4,375 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock option has an exercise price of $12.51 per share, equal to the closing price of the company’s common stock on March 13, 2026. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when such employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee’s completion of each additional month of service over the 36-month period following the first anniversary of the employment start date.

The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

More News From Schrödinger

Back to Newsroom

Schrodinger, Inc. (NASDAQ: SDGR - Get Free Report) has been given an average recommendation of "Hold" by the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company.

Posted by Defense World Staff on Apr 19th, 2026

Schrodinger, Inc. (NASDAQ:SDGR – Get Free Report) CEO Ramy Farid sold 43,000 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $12.33, for a total value of $530,190.00. Following the transaction, the chief executive officer directly owned 330,824 shares in the company, valued at $4,079,059.92. The trade was a 11.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ramy Farid also recently made the following trade(s):

On Thursday, March 5th, Ramy Farid sold 3,661 shares of Schrodinger stock. The shares were sold at an average price of $12.91, for a total value of $47,263.51. Schrodinger Trading Up 2.3% NASDAQ:SDGR opened at $12.34 on Friday. The firm has a market capitalization of $910.94 million, a price-to-earnings ratio of -8.69 and a beta of 1.62. Schrodinger, Inc. has a 1-year low of $10.94 and a 1-year high of $27.63. The business’s fifty day moving average price is $11.98 and its 200 day moving average price is $16.02.

Schrodinger (NASDAQ:SDGR – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.57. The firm had revenue of $87.24 million for the quarter, compared to analyst estimates of $83.66 million. Schrodinger had a negative return on equity of 29.47% and a negative net margin of 40.37%.Schrodinger’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.24) earnings per share. Equities analysts forecast that Schrodinger, Inc. will post -2.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth Several brokerages have weighed in on SDGR. Wall Street Zen raised Schrodinger from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Schrodinger in a research report on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of Schrodinger in a research report on Thursday, January 8th. UBS Group dropped their target price on Schrodinger from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Finally, KeyCorp dropped their target price on Schrodinger from $25.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 8th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $20.50.

Get Our Latest Stock Analysis on Schrodinger

Institutional Inflows and Outflows Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Schrodinger by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 6,464,426 shares of the company’s stock valued at $115,584,000 after acquiring an additional 125,349 shares during the last quarter. Rubric Capital Management LP increased its holdings in shares of Schrodinger by 5.4% during the 3rd quarter. Rubric Capital Management LP now owns 5,268,817 shares of the company’s stock valued at $105,692,000 after acquiring an additional 268,817 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Schrodinger by 3.5% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,714,767 shares of the company’s stock valued at $84,300,000 after acquiring an additional 160,198 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Schrodinger by 12.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,717,890 shares of the company’s stock valued at $66,476,000 after acquiring an additional 414,231 shares during the last quarter. Finally, Amova Asset Management Americas Inc. increased its holdings in shares of Schrodinger by 6.8% during the 4th quarter. Amova Asset Management Americas Inc. now owns 2,819,670 shares of the company’s stock valued at $50,359,000 after acquiring an additional 180,735 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Schrodinger Company Profile (Get Free Report)

Schrödinger, Inc is a life sciences and materials discovery company that specializes in the application of physics-based computational platforms to accelerate drug discovery and advanced materials design. Founded in 1990 by Professor Richard A. Friesner, Schrödinger has developed a suite of proprietary software tools—such as Maestro for molecular modeling, Glide for molecular docking and Jaguar for quantum chemistry calculations—that enable scientists to predict molecular behavior with high accuracy.

Featured Stories Five stocks we like better than Schrodinger

Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEInsider Selling: Nebius Group (NASDAQ:NBIS) CRO Sells $720,450.00 in Stock

NEXT HEADLINE »Magnetar Financial Llc Sells 422,762 Shares of CoreWeave (NASDAQ:CRWV) Stock

On April 22, 2026, Schrodinger Inc SDGR shares fell 4.1% today, bringing the current price to $12.35. The stock has experienced a 52-week range between $10.95 and $27.63, reflecting significant volatility and a downward trend over the past year.

GF Value™ verdict: Current price of $12.35 vs GF Value™ of $28.77, indicating a 57.1% upside.GF Score™: 69/100, which suggests the stock is performing above average relative to its peers.Most notable signal: Insiders sold $1.4M in the last 3 months, with no buying activity reported. Is SDGR Overvalued or Undervalued? According to the GF Value™, Schrodinger Inc is currently undervalued, with a fair value estimate of $28.77 compared to its current price of $12.35. This represents a significant margin of safety of 57.1%. Despite the apparent undervaluation, the GF Valuation label indicates that SDGR may be a possible value trap, suggesting investors should approach with caution. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

The current undervaluation of SDGR presents a potential opportunity for investors who are willing to navigate the risks associated with the company's financial strength and historical performance. However, it is crucial to consider the current market conditions and the stock's recent performance, which shows a year-to-date decline of 30.9% and a staggering 52.5% drop over the past year.

How Does SDGR's Valuation Compare to Its History? Metric Current Historical P/E (TTM) Not Available 55.5x Since the P/E (TTM) for Schrodinger Inc is not currently available, this section cannot provide a direct comparison with its historical valuation. However, the historical 5-year median P/E of 55.5x suggests that if the stock were to gain traction, it could potentially exceed its previous valuation levels. This lack of data means that the P/E analysis does not directly affirm or contradict the GF Value™ verdict of undervaluation.

What Does SDGR's GF Score™ Tell Us? Metric Rating GF Score™ 69 Financial Strength 5/10 Profitability 3/10 Growth 9/10 Valuation 2/10 Momentum 4/10 The GF Score™ of 69/100 indicates that Schrodinger Inc is performing above average compared to its peers, primarily driven by its strong growth rank of 9/10. However, areas of concern include its financial strength (5/10) and valuation rank (2/10), suggesting that while the company has growth potential, it may struggle with profitability and current valuation metrics.

What Are Insiders Doing with SDGR Stock? Recent insider activity shows that insiders have sold $1.4 million worth of shares in the last three months, with no buying reported. This trend may indicate a lack of confidence among insiders regarding the company's short-term performance. The absence of insider buying could be a red flag for potential investors, as it suggests that those closest to the company do not see immediate value at current price levels.

What This Means for Investors Based on the GF Value™ analysis, Schrodinger Inc is currently undervalued. However, potential investors should be cautious due to the company's financial strength and the warning of a possible value trap. The significant insider selling further complicates the investment outlook, suggesting that while the stock may present a buying opportunity, it comes with considerable risks.

For the complete analysis, visit the Schrodinger Inc SDGR stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is SDGR's GF Score™?

SDGR's GF Score™ is 69/100, indicating that the stock is performing above average relative to its peers based on key metrics.

Is SDGR overvalued or undervalued?

SDGR is currently undervalued with a GF Value™ of $28.77 compared to its current price of $12.35, suggesting a significant upside potential.

What is SDGR's P/E ratio?

The P/E ratio for SDGR is not currently available; however, its historical 5-year median P/E is 55.5x, indicating that the stock has previously traded at higher valuation levels.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

First Quarter ACV of $28 Million, Representing 12% Growth

Continued Momentum in Transition to Hosted Software Licensing

Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer

Lilly’s Announced $2.3 Billion Acquisition of Ajax Validates Schrödinger’s Track Record of High-Value Collaborations

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended March 31, 2026.

“Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth of 12 percent was driven by usage scale-ups and new deployments; we are also pleased with our progress transitioning customers to hosted licensing. The biopharmaceutical funding environment is improving, and the depth of customer engagement reflects the critical importance of our computational platform that integrates ground truth simulation with leading edge AI. We have a strong commitment to technology leadership and are excited about the release this summer of Bunsen, an agentic AI co-scientist designed to autonomously execute complex molecular discovery workflows and expand utilization to a broader user base,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “We also continue to see the impact of our platform through the success of our co-founded companies. Lilly’s announced acquisition of Ajax Therapeutics, in which we have an approximately six percent equity stake, marks another multi-billion dollar acquisition of a Schrödinger co-discovered molecule. This milestone reinforces the strength of our platform, team and integrated business model.”

First Quarter 2026 Operating and Financial Highlights (comparisons are to first quarter 2025, unless otherwise noted)

ACV was $28.4 million, a 12% increase, and $201 million on a trailing four-quarter basis. Software revenue was $35.6 million, a 21% decrease, reflecting the company’s planned accelerated transition to hosted software licensing. Drug discovery revenue was $22.9 million compared to $10.2 million, due to the accelerated recognition of deferred revenue associated with the continued progress of the company’s collaboration portfolio and the discontinuation of one collaboration program. Contribution revenue was $0.1 million, compared to $4.3 million, primarily due to completion of the predictive toxicology grant. Total revenue was $58.6 million, a 2% decrease. Software gross margin was 69%, reflecting the company’s planned accelerated transition to hosted software licensing. Operating expenses were $78.3 million, a 4% decrease. Other expenses, which include changes in fair value of equity investments and interest income/expense, were $10.8 million. Net loss was $60.0 million, compared to $59.8 million. Cash, cash equivalents, restricted cash and marketable securities were $406 million at the end of the first quarter of 2026. Schrödinger now presents contribution revenue and cost of revenue separately from software and drug discovery revenue and cost of revenues. Prior periods have been reclassified to conform to this presentation to facilitate year-over-year comparability.

2026 Financial and Operational Outlook

As of May 5, 2026, Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2026:

ACV is expected to range from $218 million to $228 million, representing 10-15% growth over 2025. Drug discovery revenue is expected to range from $55 million to $65 million. Operating expenses are expected to be less than 2025. For the second quarter of 2026, ACV is expected to range from $19 million to $23 million, exclusive of contribution ACV, compared to $23.3 million in the second quarter of 2025, which included $5.0 million of contribution ACV.

Recent Highlights

Platform

Today Schrödinger announced plans for release of an early-access version of Bunsen, its new agentic AI co-scientist, this summer. Bunsen autonomously executes complex molecular discovery workflows, expanding the user base and enhancing productivity across Schrödinger’s industry-leading computational platform. Bunsen allows for greater throughput and utilization of Schrödinger’s predict-first approaches, accelerating discovery timelines and improving project outcomes. Schrödinger’s materials science and therapeutics teams have been using Bunsen internally to enhance productivity across research projects. In April, researchers at Schrödinger and Bristol Myers Squibb published the discovery of a series of potent sterile alpha and TIR motif containing 1 (SARM1) inhibitors as a potential treatment for neurodegenerative diseases. The inhibitors were identified through a unique workflow for free-energy perturbation (FEP+). This computational approach identified molecules with unique binding properties while establishing precise dose levels to optimize safety profiles. In March, researchers at Schrödinger and Lilly published a simulation method that predicts the viscosity and injectability of antibody-based drugs by mapping interactions between individual amino acids. This computational approach replaces resource-intensive physical experiments by identifying the specific points of contact where proteins interact with one another. By computationally determining how different additives improve drug consistency, the new method can significantly accelerate the development of subcutaneous treatments. Therapeutics Portfolio

In April, Ajax Therapeutics, a company co-founded by Schrödinger, announced its sale to Lilly for up to $2.3 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones. AJ1-11095, an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor, was designed in collaboration with Schrödinger. As of December 31, 2025, Schrödinger had a 5.8% equity stake in Ajax. Schrödinger is exploring strategic partnerships for mid-and late-stage development of SGR-1505, its differentiated MALT1 inhibitor, and SGR-3515, its Wee1/Myt1 dual inhibitor. In April, Schrödinger presented preliminary Phase 1 clinical data for SGR-3515 at the American Association for Cancer Research (AACR) Annual Meeting. The initial data demonstrated that SGR-3515 was generally well-tolerated on an intermittent dosing schedule and achieved a 65% disease control rate among evaluable participants at doses of 100 mg or higher. Data most recently presented at the American Society of Hematology (ASH) Annual Meeting demonstrated that SGR-1505 was generally well tolerated and clinically active in patients with relapsed/refractory B-cell malignancies, including a 100% response rate in patients with Waldenström macroglobulinemia (WM). SGR-1505 has FDA Fast Track and Orphan Drug Designations for WM.

In March, Structure Therapeutics, a collaborator and company co-founded by Schrödinger, announced positive topline results from its Phase 2 clinical program for aleniglipron, its once-daily oral GLP-1 receptor agonist for the treatment of obesity. Schrödinger has an equity stake in Structure. Webcast and Conference Call Information

Schrödinger will host a conference call to discuss its first quarter 2026 financial results on Tuesday, May 5, 2026, at 4:30 p.m. ET. The live webcast can be accessed under “Events & Presentations" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To participate in the live call, please register for the call here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.

Non-GAAP Information

Included in this press release is certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The company presents adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation, amortization, and stock-based compensation expense, and further adjusted to exclude gains and losses on equity investments, changes in fair value of equity investments, restructuring costs, litigation and settlement expenses, and, when applicable, other non-recurring items that management does not consider indicative of ongoing operating performance.

Management believes adjusted EBITDA is a useful measure for investors, taken in conjunction with the company’s GAAP financial statements because they provide greater period-over-period comparability with respect to the company’s operating performance, by excluding the effects of capital structure, tax impacts, non-cash depreciation and amortization, non-cash equity compensation expense, non-cash mark-to-market and other valuation adjustments for the company’s equity investments, non-recurring cash distributions from the company’s equity investments, and other non-recurring items that are not reflective of the ongoing performance of the business. However, adjusted EBITDA as a non-GAAP financial measure should be considered only in addition to, not as a substitute for or as superior to, net income (loss) or other financial measures prepared in accordance with GAAP.

Other companies in Schrödinger’s industry may calculate adjusted EBITDA differently than Schrödinger does, limiting their usefulness as comparative measures. For a reconciliation of adjusted EBITDA to GAAP net income (loss), please refer to the tables at the end of this press release.

About Schrödinger

Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

Operating Metrics

To supplement the financial measures presented in this press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States (GAAP), Schrödinger also presents certain other performance metrics, such as annual contract value, or ACV, and ACV by certain industries and customer cohorts.

Annual Contract Value (ACV). Schrödinger tracks the ACV for each customer. With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period. For contracts with a duration of more than one year that are billed upfront, ACV in each period represents the total billed contract value divided by the term. ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. ACV is not intended to be a replacement for, or forecast of, revenue.

ACV by Cohorts. Schrödinger tracks ACV by certain industries and customer cohorts. These cohorts include contribution, which consists of customers from which we derive contribution revenue. We present this ACV separately because it relates to grant agreements accounted for as non-exchange contributions, rather than commercial software contracts. The operating metrics for the cohorts are not prepared in accordance with GAAP and do not correspond to the company’s reportable segments or the allocation of costs for GAAP purposes. These metrics allow management to better understand differences in sales cycles, contract duration, deployment models, renewal behavior, and expansion opportunities among customer and industry groups, supplementing but not replacing Schrödinger’s GAAP results.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its financial outlook for the fiscal year ending December 31, 2026, and second quarter ending June 30, 2026, its plans to continue to invest in research and its strategic plans to accelerate the growth of its software licensing business and advance its collaborative and proprietary drug discovery programs, the long-term potential of its business, its ability to improve and advance the science underlying its platform, the initiation, timing, progress, and results of its proprietary drug discovery programs and product candidates and the drug discovery programs and product candidates of its collaborators, the clinical potential and favorable properties of SGR-1505 and SGR-3515, its MALT1 and Wee1/Myt1 inhibitors, its plans to explore strategic opportunities for the continued clinical development of SGR-1505 and SGR-3515, potential partnering and other business development activities for its programs, the clinical potential and favorable properties of its collaborators’ product candidates, expectations relating to the potential of, and the timing of release of, Bunsen, its agentic AI co-scientist, the ability for the company to realize potential benefits from its collaborative programs, including the amount and timing of additional milestones, if any, as well as expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the demand for its software platform, its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, its ability to transition customers to hosted software deployments, factors adversely affecting the life sciences industry, fluctuations in the value of the U.S. dollar and foreign currencies, its reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of investigational new drug application submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

  Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except for share and per share amounts)

  Three Months Ended
March 31,

2026

2025

Revenues:

Software products and services

$

35,560

$

44,972

Drug discovery

22,879

10,236

Contribution

148

4,343

Total revenues

58,587

59,551

Cost of revenues:

Software products and services

10,863

9,112

Drug discovery

16,310

14,452

Contribution

1,867

4,863

Total cost of revenues

29,040

28,427

Gross profit

29,547

31,124

Operating expenses:

Research and development

43,824

45,844

Sales and marketing

11,603

10,367

General and administrative

22,914

25,802

Total operating expenses

78,341

82,013

Loss from operations

(48,794

)

(50,889

)

Other (expense) income:

Change in fair value of equity investments

(13,487

)

(13,095

)

Other income

2,663

4,204

Total other expense

(10,824

)

(8,891

)

Loss before income taxes

(59,618

)

(59,780

)

Income tax expense

408

28

Net loss

$

(60,026

)

$

(59,808

)

Net loss per share of common and limited common stockholders, basic and diluted:

$

(0.81

)

$

(0.82

)

Weighted average shares used to compute net loss per share of common and limited common stockholders, basic and diluted:

73,989,137

73,057,916

  Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except for share and per share amounts)

  Assets

March 31, 2026

December 31, 2025

Current assets:

Cash and cash equivalents

$

260,255

$

230,517

Restricted cash

7,464

6,868

Marketable securities

138,704

164,947

Accounts receivable, net of allowance for doubtful accounts of $440 and $440

27,253

83,041

Unbilled and other receivables, net of allowance for unbilled receivables of $140 and $140

20,930

21,352

Prepaid expenses

9,353

12,540

Total current assets

463,959

519,265

Property and equipment, net

20,447

19,456

Equity investments

39,826

73,647

Goodwill

4,791

4,791

Right of use assets - operating leases

100,198

102,736

Other assets

4,966

6,265

Total assets

$

634,187

$

726,160

Liabilities and Stockholders' Equity:

Current liabilities:

Accounts payable

$

11,945

$

11,452

Accrued payroll, taxes, and benefits

24,776

39,264

Deferred revenue

103,111

112,853

Lease liabilities - operating leases

16,013

16,412

Other accrued liabilities

13,697

9,155

Total current liabilities

169,542

189,136

Deferred revenue, long-term

59,019

78,877

Lease liabilities - operating leases, long-term

90,943

92,816

Other liabilities, long-term

1,135

1,278

Total liabilities

320,639

362,107

Stockholders' equity:

Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

—

—

Common stock, $0.01 par value. Authorized 500,000,000 shares; 65,383,310 and 64,515,380 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

654

645

Limited common stock, $0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

92

92

Additional paid-in capital

1,001,662

992,015

Accumulated deficit

(688,832

)

(628,806

)

Accumulated other comprehensive (loss) income

(28

)

107

Total stockholders' equity

313,548

364,053

Total liabilities and stockholders' equity

$

634,187

$

726,160

  Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

Cash flows from operating activities:

Net loss

$

(60,026

)

$

(59,808

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

Change in fair value of equity investments

13,487

13,095

Depreciation and amortization

1,476

1,589

Stock-based compensation

9,073

11,574

Noncash investment accretion

(664

)

(861

)

Loss on disposal of property and equipment

11

—

Decrease (increase) in assets:

Accounts receivable, net

55,788

215,345

Unbilled and other receivables

422

(6,332

)

Reduction in the carrying amount of right of use assets - operating leases

2,538

2,222

Prepaid expenses and other assets

4,486

(788

)

Increase (decrease) in liabilities:

Accounts payable

455

1,344

Accrued payroll, taxes, and benefits

(14,488

)

(20,616

)

Deferred revenue

(29,600

)

(10,804

)

Lease liabilities - operating leases

(2,272

)

(1,669

)

Other accrued liabilities

4,480

(228

)

Net cash (used in) provided by operating activities

(14,834

)

144,063

Cash flows from investing activities:

Purchases of property and equipment

(2,507

)

(596

)

Proceeds from disposition and sale of equity investments, net

20,334

—

Purchases of marketable securities

(34,055

)

(27,556

)

Proceeds from maturity of marketable securities

60,827

58,784

Net cash provided by investing activities

44,599

30,632

Cash flows from financing activities:

Proceeds from issuances of common stock upon stock option exercises

583

423

Principal payments on finance leases

(14

)

(14

)

Net cash provided by financing activities

569

409

Net increase in cash and cash equivalents and restricted cash

30,334

175,104

Cash and cash equivalents and restricted cash, beginning of period

237,385

162,657

Cash and cash equivalents and restricted cash, end of period

$

267,719

$

337,761

Supplemental disclosure of cash flow and noncash information

Cash paid for income taxes

$

266

$

139

Supplemental disclosure of non-cash investing and financing activities

Purchases of property and equipment in accounts payable

78

13

Purchases of property and equipment in accrued liabilities

—

25

  Reconciliation of GAAP Net Loss to Adjusted EBITDA (Unaudited)

(in thousands)

  Three Months Ended

March 31,

2026

2025

Net loss (GAAP)

$

(60,026

)

$

(59,808

)

Change in fair value of equity investments

13,487

13,095

Other income

(2,663

)

(4,204

)

Income tax expense

408

28

Depreciation and amortization

1,476

1,589

Stock-based compensation

9,073

11,574

Reorganization expense (a)

589

—

Litigation and settlement expense (b)

—

390

Adjusted EBITDA

$

(37,656

)

$

(37,336

)

Schrödinger, Inc. (SDGR) Q1 2026 Earnings Call Transcript